Medical Devices and IVDs

Device and in vitro diagnostic writing connects the device's intended purpose, design and technology, clinical or performance evidence, risk management, usability, post-market information, and lifecycle claims. The corpus emphasizes that the governing environment differs by jurisdiction, device or IVD status, risk class, lifecycle stage, and evidence route.

Classify before writing

Record:

• whether the product is a medical device or an IVD;
• intended purpose and indications;
• target population and intended user;
• use environment and operating principle;
• claims and clinical benefit;
• jurisdiction and classification or risk category;
• development, conformity-assessment, market-entry, or post-market stage;
• applicable regulations, guidance, standards, quality procedures, and templates.

The classification decision is not a writer's casual judgment. It determines the evidence and document suite and should come from the responsible regulatory and technical owners.

Clinical evaluation for devices

Clinical evaluation is a planned, continuous assessment of clinical data relevant to safety and performance. It can integrate literature, investigations, equivalence evidence where justified, post-market surveillance, complaints, vigilance, and other product data. The report must connect the intended purpose and claims to the state of the art, identified evidence, appraisal, analysis, residual risks, and clinical benefit.

High-risk areas include an underdeveloped search, weak appraisal, unjustified equivalence, reliance on irrelevant predecessor data, incomplete state-of-the-art context, untraceable claims, and conclusions that exceed the evidence. Treat literature work as reproducible evidence work and preserve searches, selection decisions, appraisal, and data extraction.

Performance evaluation for IVDs

IVD performance evaluation considers the scientific validity of the analyte-marker relationship, analytical performance, and clinical performance in relation to intended purpose. The writer should make the bridge among these evidence streams explicit and keep specimen type, target population, user, setting, comparator or reference method, performance characteristics, limitations, and claims consistent.

Diagnostic metrics require their denominators and population context. Sensitivity, specificity, predictive values, agreement, precision, limits, and invalid or indeterminate results answer different questions. Prevalence can change predictive values. Avoid presenting a single attractive metric as total performance.

Clinical investigations and performance studies

Plans and reports need clear objectives, design, sites, participants or specimens, device handling, comparators, endpoints, analysis, adverse events or deficiencies, deviations, and ethical and data-management controls as applicable. Reconcile investigation documents with risk management, instructions for use, and the intended claims.

Post-market clinical follow-up and surveillance

Post-market evidence confirms performance in use, identifies emerging risks, follows residual uncertainties, and supports lifecycle updates. Plans should start from defined evidence gaps and claims, not generic activities. Reports should show what was done, what was found, what it means for benefit-risk and state of the art, and what actions follow.

Maintain the line of sight among surveillance, vigilance, complaints, literature, trend reporting, risk-management files, clinical or performance evaluation, public summaries, and labeling. A new signal in one document should not remain invisible in another.

Device-writing QC card

Verify intended purpose, claims, classification, device identity, variants, comparator or equivalent device, state of the art, search dates, evidence tables, appraisal, risk terminology, clinical benefit, performance measures, residual risks, post-market findings, and conclusions across the suite. Confirm that every claimed performance or benefit has traceable evidence appropriate to the device and jurisdiction.